Johnson & Johnson is buying cancer drug biotech Firefly Bio for $1 billion
The deal targets KRAS-driven tumors, which J&J says have limited treatment options and survival measured in months
Overview
The deal targets KRAS-driven tumors, which J&J says have limited treatment options and survival measured in months
Source
Originally published at qz.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.
